Alkem Labs Restructures Trade Generics Business Through Subsidiary Transfer

has signed a business transfer agreement to move its trade generics business to its wholly owned subsidiary, Alkem Wellness, effective October 1, 2025, as part of its restructuring strategy. Alongside, the company received a GST order confirming a demand of ₹35.11 crore with a ₹3.5 crore penalty, which it plans to contest, clarifying that the matter has no material financial impact given adequate ITC availability. On the earnings front, Alkem delivered a strong Q1FY26 performance with revenue up 11% YoY at ₹3,371 crore, net profit surging 21.45% to ₹668 crore, and EBITDA rising 21.35% to ₹739 crore, supported by a 2.9% volume growth, highlighting operational strength despite regulatory headwinds. Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.